Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Presentations
    • Overview
    • Press Releases
    • IR Calendar
    • Safe Harbor Statement
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Management Team
    • Contacts
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Presentations
  • Overview
  • Press Releases
  • IR Calendar
  • Safe Harbor Statement
  • Email Alerts

European Commission Approves Navidea’s Sentinel Lymph Node Detection Agent Lymphoseek®

Nov 20, 2014

Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status; Platinum Partners Reaffirms Commitment to Line of Credit

Nov 11, 2014

Navidea Announces Third Quarter 2014 Financial Results

Nov 6, 2014

Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European Association of Nuclear Medicine and European Society of Surgical Oncology Meetings

Oct 30, 2014

Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014

Oct 29, 2014

Navidea Announces Rick Gonzalez as New Chief Executive Officer

Oct 15, 2014

FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors

Oct 15, 2014

Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor Conference September 30th

Sep 29, 2014

Navidea’s Lymphoseek® Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck Cancers

Sep 26, 2014

Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer

Sep 23, 2014
RSS
    • 1...
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • ...45
    © 2025 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap